Edition:
United Kingdom

Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

136.04USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$136.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
92,334
52-wk High
$149.00
52-wk Low
$95.21

Select another date:

Tue, Nov 14 2017

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

* Ligand Pharmaceuticals Inc - ‍on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc​

BRIEF-Ligand Q3 adjusted earnings per share $0.69

* Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S

BRIEF-Ligand to acquire Crystal Bioscience

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments

BRIEF-Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

* Ligand announces top-line results from Phase 2 study of LGD-6972 in patients with Type 2 diabetes

BRIEF-Ligand to receive $2 mln from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody

* Ligand to receive $2 million from WuXi Biologics for licensing clinical-stage anti-PD-1 antibody discovered using the OmniAb technology

BRIEF-Ligand Pharmaceuticals Q2 earnings per share $0.26

* Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S

BRIEF-Ligand enters into commercial license, supply agreement with Amgen

* Ligand enters into commercial license and supply agreement with Amgen for rights to use captisol in the formulation of AMG 330

BRIEF-Ligand partner Melinta Therapeutics says FDA approves antibiotic Baxdela

* ligand’s partner melinta therapeutics announces u.s. Fda approval of baxdela™ (delafloxacin) for acute bacterial skin and skin structure infections (absssi)

Select another date: